{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:30:18Z","timestamp":1786501818280,"version":"build-2736575974"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.prp.2026.156623","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:01:36Z","timestamp":1783954896000},"page":"156623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multi-omics-guided dynamic precision medicine in leukemia: An AML-centered framework integrating genotype, cellular state, bone marrow pathology, and the immune ecosystem"],"prefix":"10.1016","volume":"286","author":[{"given":"Yongchao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.prp.2026.156623_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.prp.2026.156623_bib2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.prp.2026.156623_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41375-024-02252-4","article-title":"Measurable residual disease (MRD)-testing in haematological and solid cancers","volume":"38","author":"Chen","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10238-025-01858-x","article-title":"Integrating multi-omics approaches in acute myeloid leukemia (AML): Advancements and clinical implications","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"26","key":"10.1016\/j.prp.2026.156623_bib5","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood.2023019961","article-title":"Escape from T-cell-targeting immunotherapies in acute myeloid leukemia","volume":"143","author":"Vadakekolathu","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.prp.2026.156623_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2025.06.004","article-title":"Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications","volume":"62","author":"Croese","year":"2025","journal-title":"Semin. Hematol."},{"issue":"23","key":"10.1016\/j.prp.2026.156623_bib7","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1158\/1078-0432.CCR-23-0917","article-title":"The New NCI Precision Medicine Trials","volume":"29","author":"Harris","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.prp.2026.156623_bib9","article-title":"CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies","author":"Liu","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156623_bib10","article-title":"Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy","volume":"611","author":"Jin","year":"2024","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.prp.2026.156623_bib11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.prp.2026.156623_bib12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.prp.2026.156623_bib13","first-page":"2275","article-title":"The International Consensus Classification of acute leukemias of ambiguous lineage","volume":"141","author":"Weinberg","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/hematology.2024000554","article-title":"How to think about acute leukemia of ambiguous lineage","volume":"2024","author":"Weinberg","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.prp.2026.156623_bib15","article-title":"The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions","volume":"12","author":"Iyer","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156623_bib16","article-title":"Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing","volume":"14","author":"Zhou","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41375-020-0762-8","article-title":"Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing","volume":"35","author":"Arindrarto","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-025-01438-y","article-title":"Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data","volume":"16","author":"Chang","year":"2026","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/hematology.2025000754","article-title":"Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?","volume":"2025","author":"Atluri","year":"2025","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"issue":"7","key":"10.1016\/j.prp.2026.156623_bib20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.prp.2026.156623_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41409-024-02465-2","article-title":"Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia","volume":"60","author":"Christopher","year":"2025","journal-title":"Bone Marrow Transplant."},{"issue":"24","key":"10.1016\/j.prp.2026.156623_bib22","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: how can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia?","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.prp.2026.156623_bib24","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1038\/s41588-024-01999-x","article-title":"Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype","volume":"56","author":"Lepp\u00e4","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.prp.2026.156623_bib25","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1016\/j.csbj.2025.11.066","article-title":"Whole exome sequencing and single-cell DNA sequencing for assessment of clonal heterogeneity and evolution in acute myeloid leukemia","volume":"27","author":"Adhikari","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"4","key":"10.1016\/j.prp.2026.156623_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.prp.2026.156623_bib27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.2025031480","article-title":"2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party","volume":"147","author":"Cloos","year":"2026","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"14","key":"10.1016\/j.prp.2026.156623_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35953","article-title":"Management of chronic myeloid leukemia in 2025","volume":"131","author":"Kantarjian","year":"2025","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.prp.2026.156623_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156623_bib31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3904\/kjim.2023.407","article-title":"Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy","volume":"39","author":"Yoon","year":"2024","journal-title":"Korean J. Intern. Med."},{"issue":"6","key":"10.1016\/j.prp.2026.156623_bib33","first-page":"1741","article-title":"MD-ALL: an integrative platform for molecular diagnosis of B-acute lymphoblastic leukemia","volume":"109","author":"Hu","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib34","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1038\/s41467-025-62005-4","article-title":"Epigenomic diagnosis and prognosis of Acute Myeloid Leukemia","volume":"16","author":"Marchi","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib35","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41467-025-58370-9","article-title":"Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance","volume":"16","author":"Takao","year":"2025","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.prp.2026.156623_bib36","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/s41375-025-02639-x","article-title":"The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms","volume":"39","author":"K\u00fchn","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.prp.2026.156623_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.seminhematol.2025.06.003","article-title":"Epigenetic dysregulation in acute myeloid leukemia","volume":"62","author":"Schrezenmeier","year":"2025","journal-title":"Semin. Hematol."},{"issue":"4","key":"10.1016\/j.prp.2026.156623_bib38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.ncrna.2024.05.009","article-title":"Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges","volume":"9","author":"Sharma","year":"2024","journal-title":"Noncoding RNA Res."},{"issue":"3","key":"10.1016\/j.prp.2026.156623_bib39","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.seminhematol.2025.07.001","article-title":"Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics","volume":"62","author":"Huang","year":"2025","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.prp.2026.156623_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1442539","article-title":"Multi-omic analysis of longitudinal acute myeloid leukemia patient samples reveals potential prognostic markers linked to disease progression","volume":"15","author":"Ahmed","year":"2024","journal-title":"Front. Genet."},{"issue":"5","key":"10.1016\/j.prp.2026.156623_bib41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","article-title":"Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure","volume":"32","author":"de Th\u00e9","year":"2017","journal-title":"Cancer Cell."},{"issue":"12","key":"10.1016\/j.prp.2026.156623_bib42","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.prp.2026.156623_bib43","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.prp.2026.156623_bib44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/leu.2014.252","article-title":"A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact","volume":"29","author":"Queir\u00f3s","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.prp.2026.156623_bib45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2023.11.005","article-title":"Biological, prognostic, and therapeutic impact of the epigenome in CLL","volume":"61","author":"Maiques-Diaz","year":"2024","journal-title":"Semin. Hematol."},{"issue":"12","key":"10.1016\/j.prp.2026.156623_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123349","article-title":"Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia","volume":"10","author":"Xu","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.prp.2026.156623_bib47","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41588-025-02321-z","article-title":"Rapid epigenomic classification of acute leukemia","volume":"57","author":"Steinicke","year":"2025","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib48","article-title":"Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia","volume":"5","author":"Pino","year":"2024","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib49","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1038\/s41467-024-53535-4","article-title":"Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia","volume":"15","author":"Wegmann","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.prp.2026.156623_bib50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41375-022-01796-7","article-title":"Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children","volume":"37","author":"Stratmann","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.prp.2026.156623_bib51","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.stem.2023.04.001","article-title":"Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia","volume":"30","author":"Beneyto-Calabuig","year":"2023","journal-title":"Cell. Stem Cell."},{"issue":"21","key":"10.1016\/j.prp.2026.156623_bib52","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood.2025029132","article-title":"Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia","volume":"146","author":"O'Brien","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.prp.2026.156623_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41375-024-02480-8","article-title":"Spatial transcriptomic approaches for characterising the bone marrow landscape: pitfalls and potential","volume":"39","author":"Cooper","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41698-025-00897-7","article-title":"Multimodal spatial proteomic profiling in acute myeloid leukemia","volume":"9","author":"Ly","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156623_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/PPO.0000000000000381","article-title":"Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors","volume":"25","author":"Zheng","year":"2019","journal-title":"Cancer J."},{"issue":"5","key":"10.1016\/j.prp.2026.156623_bib56","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.prp.2026.156623_bib58","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","article-title":"Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156623_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-026-01544-5","article-title":"The search for safe and effective CAR-T targets in AML","author":"Van Oers","year":"2026","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156623_bib61","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156623_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.967754","article-title":"Chimeric antigen receptor T-cell therapy for T-ALL and AML","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"issue":"10402","key":"10.1016\/j.prp.2026.156623_bib63","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib64","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1038\/s41467-023-43790-2","article-title":"Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening","volume":"14","author":"Ramos","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100060","article-title":"Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL","volume":"2","author":"Cox","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"5","key":"10.1016\/j.prp.2026.156623_bib67","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.prp.2026.156623_bib68","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.prp.2026.156623_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117024","article-title":"CAR-NK cell therapy in AML: Current treatment, challenges, and advantage","volume":"177","author":"Bahramloo","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2026.156623_bib71","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fonc.2020.00262","article-title":"A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy","volume":"10","author":"Epperly","year":"2020","journal-title":"Front. Oncol."},{"issue":"28","key":"10.1016\/j.prp.2026.156623_bib72","doi-asserted-by":"crossref","first-page":"eadw4871","DOI":"10.1126\/sciadv.adw4871","article-title":"Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML","volume":"11","author":"Gui","year":"2025","journal-title":"Sci. Adv."},{"issue":"30","key":"10.1016\/j.prp.2026.156623_bib73","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156623_bib74","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.prp.2026.156623_bib75","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2026.156623_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.764698","article-title":"The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia","volume":"9","author":"Pimenta","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"issue":"5909","key":"10.1016\/j.prp.2026.156623_bib77","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1126\/science.1164390","article-title":"Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells","volume":"322","author":"Colmone","year":"2008","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.prp.2026.156623_bib78","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.20.00475","article-title":"Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156623_bib79","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/bloodadvances.2019000792","article-title":"Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival","volume":"4","author":"Br\u00fcck","year":"2020","journal-title":"Blood Adv."},{"issue":"25","key":"10.1016\/j.prp.2026.156623_bib80","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1916206117","article-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib81","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat. Cancer"},{"issue":"7","key":"10.1016\/j.prp.2026.156623_bib82","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib83","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.prp.2026.156623_bib84","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib85","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41467-021-21445-4","article-title":"Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation","volume":"12","author":"Arenas","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156623_bib86","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-25-0531","article-title":"CD47\/SIRP\u03b1 Immune Checkpoint Modulation: A Synergistic Strategy for Next-Generation CAR Therapies","author":"Yousefi-Hashemabad","year":"2026","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.prp.2026.156623_bib87","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.prp.2026.156623_bib88","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO-25-00640","article-title":"Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML","volume":"43","author":"DiNardo","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib89","article-title":"PRC2-Related Epigenetic Age Acceleration in Acute Myeloid Leukemia with DNMT3A and IDH2 Mutations","volume":"10","author":"Yan","year":"2026","journal-title":"Adv. Biol. (Weinh. )"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-024-01096-6","article-title":"Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma","volume":"14","author":"Ziccheddu","year":"2024","journal-title":"Blood Cancer J."},{"issue":"26","key":"10.1016\/j.prp.2026.156623_bib91","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.prp.2026.156623_bib92","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjh.17185","article-title":"How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)","volume":"193","author":"Dillon","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156623_bib94","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","article-title":"Single-cell mutational profiling enhances the clinical evaluation of AML MRD","volume":"4","author":"Ediriwickrema","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.prp.2026.156623_bib95","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/10428194.2024.2422833","article-title":"Single-cell sequencing applications in acute myeloid leukemia","volume":"66","author":"Lecornec","year":"2025","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.prp.2026.156623_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102537","article-title":"Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia","volume":"14","author":"Salama","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.prp.2026.156623_bib97","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1158\/1078-0432.CCR-24-1265","article-title":"Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer","volume":"30","author":"Bang","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156623_bib98","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.prp.2026.156623_bib99","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","article-title":"LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features","volume":"5","author":"Chang","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.prp.2026.156623_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104980","article-title":"Predictive models for immune checkpoint inhibitor response in cancer: A review of current approaches and future directions","volume":"216","author":"Oisakede","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12916-019-1426-2","article-title":"Key challenges for delivering clinical impact with artificial intelligence","volume":"17","author":"Kelly","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.prp.2026.156623_bib102","article-title":"Digital twins: a new paradigm in oncology in the era of big data","volume":"5","author":"Mollica","year":"2024","journal-title":"ESMO Real. World Data Digit. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188572","article-title":"The case for AI-driven cancer clinical trials - The efficacy arm in silico","volume":"1876","author":"Kolla","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2026.156623_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14050475","article-title":"A Multidisciplinary Hyper-Modeling Scheme in Personalized In Silico Oncology: Coupling Cell Kinetics with Metabolism, Signaling Networks, and Biomechanics as Plug-In Component Models of a Cancer Digital Twin","volume":"14","author":"Kolokotroni","year":"2024","journal-title":"J. Pers. Med."},{"issue":"7","key":"10.1016\/j.prp.2026.156623_bib105","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.prp.2026.156623_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0324380","article-title":"Integrative analysis of epigenetic subtypes in acute myeloid Leukemia: A multi-center study combining machine learning for prognostic and therapeutic insights","volume":"20","author":"Li","year":"2025","journal-title":"PLoS. One"},{"issue":"12","key":"10.1016\/j.prp.2026.156623_bib107","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","article-title":"Molecular tumour boards - current and future considerations for precision oncology","volume":"20","author":"Tsimberidou","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2026.156623_bib108","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2026.156623_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102703","article-title":"Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design","volume":"125","author":"Fountzilas","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.prp.2026.156623_bib111","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood.2025030689","article-title":"Advancing the classification of hematolymphoid neoplasms together: for patients, medicine, and science","volume":"147","author":"Hasserjian","year":"2026","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010071","article-title":"Advances in DNA\/RNA Sequencing and Their Applications in Acute Myeloid Leukemia (AML)","volume":"26","author":"Ahmed","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.prp.2026.156623_bib113","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.prp.2026.156623_bib114","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.prp.2026.156623_bib115","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat. Med."},{"issue":"7382","key":"10.1016\/j.prp.2026.156623_bib117","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"7834","key":"10.1016\/j.prp.2026.156623_bib118","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib119","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat. Commun."},{"issue":"42","key":"10.1016\/j.prp.2026.156623_bib120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1200\/EDBK_359650","article-title":"Global Challenges in Access to and Implementation of Precision Oncology: The Health Care Manager and Health Economist Perspective","author":"Shih","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"10","key":"10.1016\/j.prp.2026.156623_bib121","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","article-title":"Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper","volume":"9","author":"Gagelmann","year":"2022","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.prp.2026.156623_bib122","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","article-title":"Molecular Tumor Boards in Clinical Practice","volume":"6","author":"Luchini","year":"2020","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.prp.2026.156623_bib123","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41576-021-00370-8","article-title":"Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics","volume":"22","author":"Longo","year":"2021","journal-title":"Nat. Rev. Genet."},{"issue":"12","key":"10.1016\/j.prp.2026.156623_bib124","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156623_bib125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13073-019-0701-3","article-title":"Digital twins to personalize medicine","volume":"12","author":"Bj\u00f6rnsson","year":"2019","journal-title":"Genome Med."},{"issue":"12","key":"10.1016\/j.prp.2026.156623_bib126","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/s41591-021-01558-5","article-title":"Digital twins for predictive oncology will be a paradigm shift for precision cancer care","volume":"27","author":"Hernandez-Boussard","year":"2021","journal-title":"Nat. Med."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:26:08Z","timestamp":1786501568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":126,"alternative-id":["S0344033826002761"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156623","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-omics-guided dynamic precision medicine in leukemia: An AML-centered framework integrating genotype, cellular state, bone marrow pathology, and the immune ecosystem","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156623"}}